|
Name |
Pyripyropene O
|
Molecular Formula | C29H35NO7 | |
IUPAC Name* |
[(1R,2S,5S,6R,7R,10R)-5-acetyloxy-2,6,10-trimethyl-16-oxo-14-pyridin-3-yl-11,15-dioxatetracyclo[8.8.0.02,7.012,17]octadeca-12(17),13-dien-6-yl]methyl acetate
|
|
SMILES |
CC(=O)OC[C@]1([C@@H]2CC[C@@]3([C@@H]([C@]2(CC[C@@H]1OC(=O)C)C)CC4=C(O3)C=C(OC4=O)C5=CN=CC=C5)C)C
|
|
InChI |
InChI=1S/C29H35NO7/c1-17(31)34-16-28(4)23-8-11-29(5)24(27(23,3)10-9-25(28)35-18(2)32)13-20-22(37-29)14-21(36-26(20)33)19-7-6-12-30-15-19/h6-7,12,14-15,23-25H,8-11,13,16H2,1-5H3/t23-,24-,25+,27+,28+,29-/m1/s1
|
|
InChIKey |
LNZRIIIDRGIMHV-QXHZFDHFSA-N
|
|
Synonyms |
Pyripyropene O; [(1R,2S,5S,6R,7R,10R)-5-Acetyloxy-2,6,10-trimethyl-16-oxo-14-pyridin-3-yl-11,15-dioxatetracyclo[8.8.0.02,7.012,17]octadeca-12(17),13-dien-6-yl]methyl acetate
|
|
CAS | NA | |
PubChem CID | 10553713 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 509.6 | ALogp: | 4.0 |
HBD: | 0 | HBA: | 8 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 101.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 37 | QED Weighted: | 0.521 |
Caco-2 Permeability: | -4.996 | MDCK Permeability: | 0.00001970 |
Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.335 |
30% Bioavailability (F30%): | 0.987 |
Blood-Brain-Barrier Penetration (BBB): | 0.197 | Plasma Protein Binding (PPB): | 81.04% |
Volume Distribution (VD): | 1.025 | Fu: | 19.71% |
CYP1A2-inhibitor: | 0.25 | CYP1A2-substrate: | 0.204 |
CYP2C19-inhibitor: | 0.207 | CYP2C19-substrate: | 0.519 |
CYP2C9-inhibitor: | 0.445 | CYP2C9-substrate: | 0.235 |
CYP2D6-inhibitor: | 0.119 | CYP2D6-substrate: | 0.203 |
CYP3A4-inhibitor: | 0.81 | CYP3A4-substrate: | 0.491 |
Clearance (CL): | 2.533 | Half-life (T1/2): | 0.404 |
hERG Blockers: | 0.449 | Human Hepatotoxicity (H-HT): | 0.819 |
Drug-inuced Liver Injury (DILI): | 0.834 | AMES Toxicity: | 0.011 |
Rat Oral Acute Toxicity: | 0.086 | Maximum Recommended Daily Dose: | 0.443 |
Skin Sensitization: | 0.483 | Carcinogencity: | 0.038 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.474 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005020 | 0.806 | D06CNP | 0.348 | ||||
ENC002192 | 0.737 | D02STN | 0.281 | ||||
ENC002198 | 0.627 | D02CJX | 0.271 | ||||
ENC003422 | 0.511 | D02CNR | 0.268 | ||||
ENC003130 | 0.500 | D0X4RS | 0.264 | ||||
ENC002118 | 0.489 | D09WYX | 0.257 | ||||
ENC003423 | 0.467 | D08BDT | 0.256 | ||||
ENC001980 | 0.457 | D0V2JK | 0.255 | ||||
ENC002412 | 0.434 | D0T6WT | 0.252 | ||||
ENC002080 | 0.408 | D0W5LS | 0.250 |